Tissue Repair Ltd
TRP.ASXHealth Care
Tissue Repair is a clinical stage biopharmaceutical company developing an advanced wound healing technology targeting applications in the chronic wound and cosmetic procedure markets.
Market Data
$0.110
-0.1%$6.7M
-100000.0x
$-0.064
0.00%
-0.6%
Latest Earnings
Appendix 4D and Half Year Report to 31 December 2025
27 February 2026
Tissue Repair Ltd (ASX: TRP), a clinical-stage biopharmaceutical company, reported a half-year loss of $2.17M for the period ending 31 December 2025, a 15.1% improvement on the prior period loss of $2.56M. Revenue from contracts with customers grew 54.5% to $305,820, driven by the July 2025 distribution agreement with Advanced Cosmeceuticals for the TR Pro+® product. Cash reserves stand at $8.29M, declining from $12.32M at the start of the period, reflecting ongoing investment in Phase 3 clinical trials and R&D operations. Key points: Product revenue grew 54.5% to $305,820, reflecting early commercial traction from the TR Pro+® distribution agreement with Advanced Cosmeceuticals signed July 2025.; Net loss improved by 15.1% to $2.17M (vs $2.56M pcp), indicating better cost control across G&A (down from $406K to $126K) and advertising/marketing (down from $195K to $53K).; Advanced Cosmeceuticals reported sales exceeding 3,000 tubes of TR Pro+ 10g in November 2025, providing early validation of commercial channel.
Recent Announcements
Appendix 4D and Half Year Report to 31 December 2025
Tissue Repair Ltd (ASX: TRP), a clinical-stage biopharmaceutical company, reported a half-year loss of $2.17M for the period ending 31 December 2025, a 15.1% improvement on the prior period loss of $2.56M. Revenue from contracts with customers grew 54.5% to $305,820, driven by the July 2025 distribution agreement with Advanced Cosmeceuticals for the TR Pro+® product. Cash reserves stand at $8.29M, declining from $12.32M at the start of the period, reflecting ongoing investment in Phase 3 clinical trials and R&D operations. Key points: Product revenue grew 54.5% to $305,820, reflecting early commercial traction from the TR Pro+® distribution agreement with Advanced Cosmeceuticals signed July 2025.; Net loss improved by 15.1% to $2.17M (vs $2.56M pcp), indicating better cost control across G&A (down from $406K to $126K) and advertising/marketing (down from $195K to $53K).; Advanced Cosmeceuticals reported sales exceeding 3,000 tubes of TR Pro+ 10g in November 2025, providing early validation of commercial channel.
Get real-time alerts for TRP
Receive AI-powered earnings summaries and instant notifications when Tissue Repair Ltd releases results.
Register Free